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 Summary
 Background: The aim of this study was to evaluate the alterations in the neoplastic tissue of GIST following 
Imatinib treatment.
 Material/Methods: CT studies of 14 patients with inoperable primary tumors and 56 patients with metastatic and 
recurrent disease after chemotherapy were analyzed retrospectively. The following alterations in 
features of primary and secondary tumors were analyzed: dimension, degree and type of contrast 
enhancement, outlines of lesions, presence of intratumoral bleeding, presence of calcifications.
 Results: In the analyzed group of primary, metastatic and recurrent tumors after treatment with Imatinib 
in most cases a decrease in size and contrast enhancement were observed; the outlines of 
lesions became well circumscribed. Following the treatment, the number of tumors enhancing 
inhomogeneously decreased. In primary tumors the percentage of calcifications increased, whereas 
in metastatic tumors calcifications were observed only after treatment. There was no bleeding 
found within primary tumors after treatment. In metastatic disease, increased percentage of 
tumors with transient intratumoral bleeding was observed. There were also some unconventional 
CT images following treatment, such as: cystic transformation of lesions, enlargement of lesions, 
appearing of new lesions suggesting progression of the disease, stationary dimensions of lesions 
during local progression of the disease, simultaneous decrease and increase in size of metastatic 
lesions or appearance of new ones.
 Conclusions: Right from the start of Imatinib therapy in inoperable and disseminated GIST patients, specific CT 
images, not seen during conventional cytotoxic chemotherapy, were observed.
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Background
Gastrointestinal stromal tumor (GIST) is the most com-
mon gastrointestinal tumor of mesenchymal origin. GIST 
may develop in every part of the gastrointestinal tract, but 
mostly occurs in the stomach (50–60% of cases) and in the 
small intestine (30–35% of cases). Less often it occurs in the 
colon and rectum (5% of cases), and in the esophagus (<1% 
of cases) [1]. In less than 5% of cases GISTs arise from the 
omentum, mesentery and retroperitoneal space [2].
Until recently, the only treatment method of GIST was 
radical surgical resection of the primary lesion. In turn, 
the treatment effects of inoperable or disseminated GIST 
were very bad (median overall survival 9 to 20 months 
after disease recurrence). In recent years, the break-
through occurred, thanks to introduction of new treat-
ment with Imatinib Mesylate (commercial name Glivec) 
[3–5]. Imatinib is a phenylaminopyrimidine derivative, its 
mechanism of action depends on blocking of ATP bind-
ing by tyrosine kinase. This action is breaking the sig-
nal cascade of the main pathway stimulating the tumor 
growth. Imatinib is a selective inhibitor of three tyrosine 
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kinases: the Bcr kinase, c-KIT kinase and the PDGFRA 
kinase. Thanks to the discovery of crucial impact of c-KIT 
and PDGFRA receptor activation on development of GIST, 
Imatinib-based causal treatment could be applied. This 
therapy was earlier successfully used against chronic mye-
loid leukemia. Therefore, GIST became the first solid tumor 
treated effectively with targeted molecular therapy. The 
first use of Imatinib took place in 2001. After a series of 
clinical trials, the drug was allowed for sale in 2002, as a 
first-line treatment of advanced GIST. Imatinib is a repre-
sentative of a modern group of anti-tumor cytostatic drugs. 
It is not a conventional cytostatic drug (the one that is used 
in wide spectrum of neoplasms and has significant side 
effects), it is targeted against a specific tumor type, bearing 
much smaller general toxicity. The benefits of treatment 
with Imatinib in advanced stages of GIST are unquestion-
able. The rate of positive responses to therapy ranges from 
70 to 80%. Partial response (PR) is the most common – more 
than 50% of patients, and stable disease (SD) occurs in 30%. 
Complete remission occurs only in sporadic cases (about 
3–6%), which is due to drug’s mechanism of action that 
does not cause direct cell death.
Treatment response assessment in GIST tumors during 
molecular targeted therapy is the new problem in radiol-
ogy, because of the fact that atypical radiological images 
may occur, unprecedented so far in conventional cytostatic 
therapies. Generating of these images is caused by different 
mechanisms of action of drugs and developing secondary 
resistance. Their improper interpretation, caused by rigid 
application of treatment response criteria based on changes 
of the tumor size, can result in drug withdrawal and pre-
term patient’s death.
It has been shown in recent years, that traditional RECIST 
and WHO criteria, based just on changes of the tumor size, 
are sometimes inadequate in assessment of effectiveness 
of modern molecular-based targeted therapy. Changes 
in blood supply and metabolism of neoplastic tissue after 
treatment, reflected by contrast enhancement in comput-
ed tomography, can significantly precede changes of the 
tumor size. Often enough a good response to chemotherapy 
is only visible as decrease in tumor enhancement without 
reduction of lesion diameter. Application of the RECIST 
criteria may lower treatment response rates and in conse-
quence lead to withdrawal of the drug in patients who ben-
efit from the therapy. After the criteria assessing therapy-
induced tumor response rates were assessed as inadequate, 
the Choi classification was introduced. This classification, 
apart from changes in the tumor diameter, includes also 
changes in attenuation in the venous phase of dynamic CT 
scan.
Aim of the study
The goal of the study was to evaluate in CT alterations in 
neoplastic tissues in the course of GIST in the course of 
Imatinib therapy.
Material and Methods
Retrospective analysis of changes that occurred in tissues 
of primary tumors and metastases due to treatment with 
Imatinib. In the whole analyzed group, there were availa-
ble CT scans of 14 patients with inoperable primary tumors 
during chemotherapy and studies of metastatic lesions 
and recurrences in 56 different patients, but in 8 of them 
there were both metastases and primary lesion in the same 
time (62 patients in total). There was an equal number of 
females and males in the analyzed group, with a median 
age of 61 years. The youngest patient was 14 years old 
when she got ill – it is an extremely rare case of pediatric 
GIST; while two oldest patients were 86 years old.
The CT scans were performed at the Department of 
Imagine Studies, University Hospital in Cracow, using 
spiral multiple-row CT scanner – Siemens Sensation 16. 
Patients were prepared by oral administration of con-
trast medium Urografin 76%, in amount of 25 mL per liter 
of water in two doses: 0.5 liter for night on the day pre-
ceding the study and 0.5 liter two hours before the study. 
Additionally, the patients were given 0.25 liter of solution 
(5 mL of Urografin per glass of water) right before the scan 
to contrast the gastrointestinal tract.
The studies were performed with the following parameters: 
• layer thickness 5 mm;
• pitch 0.75;
• increment 5 mm.
In every patient 3D reconstructions (2-mm distance 
between layers) were performed from raw data obtained 
during acquisition. The data were processed using Syngo 
CT2006G console.
The imaging was made after intravenous administration of 
contrast media Omnipaque or Iomeron, concentration 350 
mg/ml, 1 ml per kilogram of body weight, using an auto-
matic syringe with a flow rate of 2.5 ml/s; in dynamic, 
triphasic setting:
• before injection of contrast agent – plain scan;
• on arterial phase (after 20–25 seconds after injection);
• on portal venous phase (after 50–60 seconds);
•  on delayed phase (after 5–7 minutes of injection of con-
trast agent)/
Changes of tumors’ features in CT that occurred during 
therapy in the whole observation period were analyzed 
(median time over two years):
• size (reduction, increase, stationary lesion);
•  contrast enhancement level (no enhancement/very low, 
low/medium, high);
•  type of contrast enhancement (heterogeneous or margin-
al/homogenous/no enhancement);
• lesion contours (well defined/poorly defined);
• presence of bleeding within tumor (yes/no);
• presence of calcifications (yes/no).
Results
Analysis of alterations visible in CT examination in prima-
ry GIST tumors prior and after the therapy are depicted in 
Tables 1 and 2.
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All the lesions shrank following the treatment. Their con-
trast enhancement in most of the cases decreased, apart 
from two tumors in which it remained unchanged.
Prior treatment, the tumors had inhomogeneous contrast 
enhancement (including peripheral).
Following therapy, 21% of lesions had no contrast enhance-
ment anymore and number of lesions with inhomogeneous 
enhancement decreased to 64%.
Two lesions (14.3%) were enhancing homogenously.
Tumor enhancement level before the treatment was 
mostly average or high (93%). One of the lesions was low-
enhancing (7%). Following therapy, average or high contrast 
enhancement remained in 36% of lesions, in 43% became 
low or very low.
The lesions’ contours in 21% of cases became almost well-
defined (7% prior therapy), and in the rest of the cases they 
were still irregular 79% (93% before treatment).
The percentage of calcifications in tumor mass increased 
from 29% to 36% of cases.
There was no bleeding within primary tumor mass neither 
before nor following therapy.
Figure 1 shows typical alterations in primary GIST image 
following treatment (after three months of therapy).
To reassume, primary GIST tumors’ size decreases follow-
ing therapy, as well as their contrast enhancement level. 
After injection of contrast agent, the enhancement pattern 
becomes more homogenous. Whatsmore, the contours of 
primary lesions after treatment became more defined, with 
increased number of calcifications inside them.
Next, the features of metastatic lesions or local recur-
rence were analysed, before and after treatment. Data are 
shown in Tables 3 and 4. In Table 3 we analysed altera-
tions in size, conrast enhancement level and corelations 
between these variables. In Table 4 we analysed features 
of GIST metastases following therapy, such as: type and 
level of contrast enhancement, lesions’ contours, presence 
of bleeding and calcifications, cyst mimicking and tumor 
isodensity.
Following chemoterapeutic treatment, most of the lesions 
decreased (75%), and in 14% of cases remained stationary. 
Only in 11% of the cases, the size of lesions increased.
In 79% of cases, contrast enhancement level decreased, in 
14% it remained stationary, and in 7% increased.
Mostly, metastatic lesions shrank as well as their contrast 
enhancement deceased (71%). Less than 4% of lesions grew 
and increased contrast enhancement.
Changes in the size and contrast enhancement of the primary tumors following 
therapy Quantity Percentage [%]
Size Shrank 14 100.0%
Contrast enhancement
Decreased 12 85.7%
Stationary 2 14.%
Table 1. The alterations in the size and contrast enhancement of the primary GIST following therapy (14 patients).
Features of the primary GIST tumors
Prior therapy Following therapy
N % N %
Enhancement pattern
Inhomogenous or marginal 13 100.0 9 64.3
Homogenous – – 2 14.3
No enhancement – – 3 21.4
Level of enhancement
Very low or low 1 7.1 6 42.9
Average or high 13 92.9 5 35.7
No enhancement – – 3 21.4
Contours
Well defined 1 7.1 3 21.4
Poorly defined 13 92.9 11 78.6
Bleeding – – – –
Calcifications 4 28.6 5 35.7
Table 2. The alterations in features of the primary GIST following therapy.
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Figure 1.  Axial CT scans of GIST in the stomach before (A) and after 3 months (B) of chemotherapy with Imatinib.
Metastases
Size
Overall
Decreased Stationary Increased
Contrast enhancement level
Decreased
Quantity 40 2 2 44
Percentage 71.4% 3.6% 3.6% 78.6%
Stationary
Quantity 2 4 2 8
Percentage 3.6% 7.1% 3.6% 14.3%
Increased
Quantity - 2 2 4
Percentage 0% 3.6% 3.6% 7.1%
Overall
Quantity 42 8 6 56
Percentage 75.0% 14.3% 10.7% 100.0%
Table 3. The relation between the size and contrast enhancement after treatment of the metastases in the course of GIST.
 Features of metastases
Before treatment During treatment
N % N %
Enhancement type
Inhomogenous or marginal 49 87.5 25 44.6
Homogenous 7 12.5 5 8.9
No enhancement – – 26 46.4
Enhancement level
Very low or low 7 12.5 15 26.8
Avereage or high 49 87.5 15 26.8
No enhancement – – 26 46.4
Contours
Well defined 6 10.7 22 39.3
Poorly defined 50 89.3 34 60.7
Bleeding 2 3.6 7 12.5
Calcifications – – 2 3.6
Cyst mimicking 4 7.1 28 50.0
Isodensity 1 1.8 13 23.2
Table 4. The alterations in features of the metastatic tumors in course of GIST during chemotherapy.
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Before treatment, 87.5% of lesions were inhomogeneously 
(including marginally) enhancing, in 12.5% homogeneously. 
Following treatment, 46% of lesions did not show charac-
teristics of contrast enhancement, 54% still enhanced inho-
mogeneously (44%) or homogeneously (9%).
Before treatment 87.5% of lesions enhanced after injec-
tion of contrast agent (high and average enhancement 
level, 12.5% low or very low). In course of treatment in 
nearly half of cases, contrast enhancement disappeared 
after a few months, which was associated with very good 
response to drug. The remaining tumors were still enhanc-
ing low or very low (27%), or in average or high level (27%).
The contours of lesions in 39% of cases became well-
defined (before treatment only in 11%).
The features of temporary bleeding into lesions appeared 
in the course of treatment in 12.5% of cases (4% before 
treatment).
Calcifications were visible only in treated metastatic 
lesions (4% of cases).
Temporarily isodense lesions occurred more often during 
treatment (23% of cases) than before therapy (2%).
After several months of treatment half of the lesions had 
similar image to cystic changes (50%), before treatment 
such an image was sporadic (7%). Probably that was the 
reason why in two cases the treated metastases in the liver 
were described as simple cysts of this organ. There were 
also descriptions of cysts in the mesentery and fluid col-
lection in the lesser pelvis. In reality those were peritoneal 
metastases, in which attenuation decreased significantly 
because of therapy, so they started to look like pseudocysts.
Evaluating changes in attenuation and size of neoplastic 
lesions in the course of treatment in the whole observation 
period (median time about 2 years) in the group respond-
ing positively to treatment (PR), higher decrease in median 
attenuation than lesion size was found.
It was noticed that this process occurs most rapidly in the 
first 3 months after applied treatment.
Figure 2 shows alterations in image of metastatic lesions 
following Imatinib chemotherapy with development of 
“pseudocystic” image.
Because of “pseudocyst” phenomenon, CT scans of patients 
during chemotherapy (62 persons) were analyzed in search 
of other images of neoplastic pseudoprogression. Data is 
shown in Table 5. Images mimicking progression consist 
of appearance of “new” lesions or increasing size of lesions 
already present despite good response to treatment of neo-
plastic tissue. In the analysed group of patients decrased 
attenuation after therapy was considered as a good respose 
to treatment.
In overall, 11 cases of pseudoprogression were noticed, 
including its both types in one patient in the same time, 
A B
Figure 2.  Axial CT scans in the venous phase of the dynamic study of the liver GIST metastases before (A) and after 3 months of chemotherapy (B).
Pseudoprogression images (with good response to treatment) Quantity Percentage [%]
Increase of lesions – size pseudoprogression 2 3.6
Appearance of “new” lesions – number of cases of pseudoprogression 9 16.1
-including both types of pseudoprogression 1
No pseudoprogression image 45 80.0
Overall 56 100.0
Table 5. The occurrence of the images mimicking progression of lesions in the evaluated group of patients.
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which represents 20% of all images of good response to 
treatment. In 4% of patients, lesion size increased, in 16% 
“new” lesions appeared.
There was enlargment of metastases in the first control 
examination in another 2 patients from the analyzed group 
despite good response to treatment but it did not exceed 
20% of the sum of largest lesion diameters, so it was not 
classified as a progression in RECIST scale.
In 9 patients appearance of “new” weakly attenuating 
lesions in the liver was found in the course of treatment. In 
2 patients it was visible in the first control examinations.
In the rest of the patients such images were found in fur-
ther examinations (some patients had no available control 
examinations in the first 4 months of treatment).
Figure 3 shows examples of pseudoprogression of neoplas-
tic process – appearance of “new” lesions in the liver after a 
few months of treatment.
Figure 4 shows example of metastatic lesion size pseudo-
progression in the liver after 2 months of treatment, with 
simultaneous decrease in attenuation in the venous phase 
of dynamic CT scan.
Discussion
In the analyzed group of primary tumors that underwent 
treatment (14 cases), dimensions of all tumors decreased, 
as well as their attenuation (86%). Contrast enhancement 
of most of the lesions after treatment was low (43%) or 
absent (21%). The remaining 36% still expressed significant 
contrast enhancement, but it was lower than in baseline 
examinations, apart from two cases in which it remained 
stationary. In the course of treatment, the percentage of 
calcifications inside lesions increased from 29% to 36%.
In the analyzed group of metastases and local recurrenc-
es (56 cases), similarly to primary tumors, most of the 
lesions shrank (75%) and showed decreased attenuation in 
the course of treatment (79%). As much as 46% of lesions 
did not enhance at all, and the remaining ones enhanced 
low or very low. The lesions, which held on to strong con-
trast enhancement did not response to treatment (18%) 
or responded only by decreasing their dimensions (4%). 
Contours of lesions became well defined in 39% of cases 
(11% of cases before treatment). A certain group of metas-
tases developed calcifications in the course of treatment 
(4%). Features of temporary hemorrhage were more fre-
quently seen after treatment (12.5%) than before (4%). In 
two cases lesions enlarged more than 20% from the starting 
point with simultaneously decreased attenuation. In anoth-
er two cases lesions enlarged but less than 20%.
In total, this constitutes 4 cases of false lack of response 
to treatment according to RECIST criteria, of which two 
would be classified as a progression, despite good response 
to drug. Therefore, to evaluate tumors after applied treat-
ment, the Choi classification was introduced, according to 
which the lesion positively responding to treatment is the 
one, that decreases its dimensions by at least 10% or when 
contrast enhancement decrease inside the lesion is 15% or 
more.
Decrease in attenuation and size of neoplastic lesions in 
the analyzed group of lesions well responding to treatment 
during the whole observation period was largest during 
the first months of observation. In the third month after 
drug administration, median decrease in enhancement was 
about 40%, and median decrease in size about 20%. Both of 
those values were still decreasing in further observation, 
but not significantly.
In the group of 44 tumors investigated by Choi et al. 
in 2007, lesion attenuation after two months of thera-
py decreased by 31% on average in PR group, and lesion 
dimensions decreased by 26% on average. Those values 
were very similar to the ones in the analyzed group [6].
Betchold et al. noticed an average decrease in lesion atten-
uation of 47% in the second month of treatment (60 to 32 
HU), and of 62% in the twelfth month [7].
A B
Figure 3.  Axial CT scans during the venous phase of dynamic study before (A) and during chemotherapy (B); the “ new “ lesions are discernible 
within VI segment of the liver.
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Similarly, Sandrasegaran et al. reported that most signifi-
cant decrease in size of lesions took place during the first 3 
months of treatment [8].
The most common unconventional tomographic image, 
which can be the reason for diagnostic mistakes in 
evaluation of GIST treated with Imatinib, is the cystic 
transformation.
In the analyzed group of lesions, half of metastases in the 
course of treatment converted into lesions mimicking cysts, 
both in the liver and peritoneum. Those lesions did not 
enhance or had minimal contrast enhancement, had well-
defined contours and interior attenuation values typical 
for liquids. The level of similarity between metastases and 
simple cysts was sometimes so high that wrong descrip-
tions of such lesions in CT scans occurred (most often this 
referred to hepatic simple cysts and one mesenteric cyst), 
mostly in cases when there was no data on the diagnosis 
and treatment method in the referral letter. There was one 
case of interpreting fluidized metastasis in the pelvis as a 
free fluid in the peritoneal fold, with complete remission of 
lesions after treatment.
In case of metastases located in the peritoneum, detec-
tion and evaluation of lesions with cystic transformation, 
among liquid-filled bowel loops, is difficult. Proper fill-
ing of bowel loops with positive contrast agent can reduce 
these difficulties. What is more, due to mobility of the mes-
entery, metastases can migrate inside the abdominal cavity 
A
C
B
D
Figure 4.  Axial CT scans in the venous phase of dynamic study of the metastatic lesion in the liver before (A, B) and after 2 months of therapy with 
Imatinib (C, D).The dimensions of the lesion increased from 12 mm to 21 mm (linear dimension),while the density of the lesion decreased 
from 41 HU to 28 HU (ROI).
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and pelvis; changes in their shape are also possible, which 
causes additional difficulties in evaluation.
Transformation of primary solid metastases in the liver 
into lesions mimicking simple cysts due to myxoid degen-
eration of neoplasm is a frequent phenomenon and was 
described in many articles [7,9–13].
Usually, attenuation of such lesions is a bit higher 
than of true cysts, which helps in differentiation [14]. 
Nevertheless, in the analyzed group we observed tumors 
with attenuation of a few to a dozen of HU, making them 
impossible to distinguish from real cysts based on the 
attenuation values only.
Sadragesian et al. found that 67% of hepatic metastases 
after three months of treatment looked like non-enhancing 
cystic lesions without internal echoes, and those lesions 
were often mistakenly described by radiologists as simple 
cysts [8].
Yang et al. described transformation of metastases into 
pseudocysts with clearly discernible contours of lesions, 
which had features of simple cysts also in ultrasonogra-
phy, additionally increasing the chance of misinterpretation 
[15]. Similar transformations of solid tumors into pseudo-
cystic lesions in CT scans were shown by Patnaik et al. [16].
Additional aspect of fluidization of metastases is the fact 
that according to RECIST criteria cystic lesions are consid-
ered to be “unmeasurable”, and should not constitute tar-
gets measured in order to evaluate response to treatment, 
because changes in size of cysts do not necessarily cor-
relate with the effect of the drug. The problem is serious 
because most of the GIST metastases undergo necrosis and 
cystic degeneration in the course of treatment. Usually in 
such cases there are no lesions that would remain solid in 
the course of treatment and whose changes in size could be 
followed according to RECIST criteria.
Difficulties described above do not occur when treatment 
response is evaluated according to Choi criteria, because 
decrease in attenuation occurring during fluidization of 
the lesions is the criterion of good response to treatment, 
regardless of the changes in their size.
Some authors suggest update of the criterion used by Choi, 
considering partial response as a relative decrease by at 
least 15% of lesion’s attenuation, by adding a criterion of 
unconditional decrease by at least 10 Hounsfield Units [17].
Another unconventional tomographic image that can 
become the reason of diagnostic errors in evaluation of 
GIST tumors treated with Imatinib is enlargement of 
lesions during actual regression of disease (pseudoprogres-
sion). Such an image is considered in RECIST as progres-
sion of the disease. There is no threat of false interpretation 
of such lesions when Choi criteria are used because all the 
“growing” lesions that in fact response well to the therapy 
decrease their attenuation.
In the analyzed group, there were in total 4 cases of lesion 
enlargement accompanying good response to treatment, 
which resulted in qualifying two of them, according to the 
RECIST scale, to the group of patients with progression (4% 
of all patients), and the remaining two to the group with 
a stable disease, because lesion enlargement amounted for 
less than 20%. In all of those cases, attenuation measured 
during the venous phase of the CT scan decreased sig-
nificantly, especially in case of hepatic lesions that devel-
oped the image of pseudocysts (3 cases). All those lesions 
decreased in the second control examination, apart from 
one lesion, which remained stationary.
Rare cases of enlargement of tumors treated with Imatinib, 
despite good response to therapy (caused by rapid myxo-
id degeneration, necrosis or hemorrhage into the lesions), 
are described in papers, and the time that elapsed before 
the lesions stopped to enlarge was usually about 4-8 weeks 
(1–2 cycles of chemotherapy) [11,15,10,18–20].
Another unconventional CT image that can cause diag-
nostic errors in evaluation of GIST tumors treated with 
Imatinib is appearance of “new” changes suggesting disease 
progression during actual regression (pseudoprogression). It 
is caused by the fact that previously isodense, usually small 
metastases in the liver that decreased their attenuation in 
the course of treatment get visible, and therefore become 
detectable.
In the analyzed group of lesions such images of appearing 
“new” metastatic lesions in the liver were found in as many 
as 16% of treated tumors. In two cases it occurred already 
in the first control examination and resulted in qualify-
ing the patients to group with progression (PD) based on 
RECIST criteria. In the remaining patients this was dis-
cernible in scans performed later than 3 months from the 
beginning of the treatment. All those new lesions had low 
internal attenuation and resembled in some degree tiny 
cysts in the liver. Sometimes such images were noticeable 
periodically because tiny hypodense lesions were becom-
ing isodense with liver tissue or were decreasing so much 
that they could not be visualized anymore. Images of simi-
lar pseudoprogression probably occur in case of peritoneal 
metastases but were not seen due to difficulties with their 
noticing.
Descriptions of similar, rare cases of appearance of pseudo-
new lesions in the liver are also published in papers [10,12].
Due to appearance of images of pseudoprogression (size and 
number) in the course of Imatinib GIST treatment it would 
be difficult to agree with conclusions made by Le Cesne et 
al. who claimed that the criterion of lack of progression 
according to RECIST classification is sufficient to distin-
guish patients with good response to treatment [21].
According to RECIST, patients with a false image of pro-
gression would be included in the group with disease pro-
gression (PD). Therefore, the criterion of alterations in 
tumor attenuation in the course of treatment cannot be 
omitted.
Tomographic images that could lead to diagnostic errors 
in the assessment of GIST tumors treated with Imatinib 
include temporary “disappearance” of metastases in CT 
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scans as a result of diminishing their primary high attenu-
ation, which then becomes isodense with the surrounding 
hepatic tissue. In the analyzed group of changes, temporary 
isodensity of metastatic lesions was present in as much as 
23% of cases. This more often concerned small, single (or 
few) lesions in the same patient, who had remaining meta-
static lesions visible anyway. Only in one case, all of the 
primarily well-enhancing lesions decreased their enhance-
ment in the course of treatment, becoming isodense with 
the hepatic tissue for the period of a few months, so that 
it was difficult to measure their size and attenuation with-
out referring to images prior injection of contrast agent, in 
which they were still (although weakly) visible. Such imag-
es can lead to qualifying the patient to the group with com-
plete remission (CR).
In the analyzed group, we observed that metastases 
behaved in different ways in the course of treatment. 
Several patients had typical pseudocystic, non-enhancing 
lesions in the liver, coexisting with lesions with persistent 
(although decreased) contrast enhancement (3). What is 
more, in control examinations after a few to dozen or so 
months of treatment, we observed single cases of changes 
of different degree in the size of metastases in the same 
patient, as well as shrinkage of the lesions in the liver with 
simultaneous slow growth of the lesions in the peritone-
um, or simultaneous shrinkage of some metastases with 
enlargement of the others in the same location (peritoneum 
or liver). Cases described above pose difficulties in radio-
logic evaluation of the treatment effect.
Phongkitkarun et al. found among 18 treated patients one 
case in which they claimed growth of lesions in the peri-
toneum, with lesions in the liver converting into cystic 
lesions that reduced their size [22].
Changes in the size of one of primary tumors were another 
problem in the analyzed group of GIST tumors. This was 
patient’s only visible neoplastic lesion, which periodically 
evacuated its necrotic masses into the jejunum, thus chang-
ing its size inadequately to actual response to treatment of 
such tumor tissues. Based on own experience, we advise 
measuring wall thickness instead of total dimensions.
Tomographic image which can become a cause of diagnos-
tic errors in GIST lesions treated with Imatinib is a sta-
tionary image of lesions during actual progression. Primary 
lesions with inner clonal expansion of cells that have lost 
sensitivity to drug – “tumors within a tumor” images – 
usually retain their external dimensions. This has been 
described in many papers [1,6,18,23–25].
In the analyzed group of GISTs there was a frequent phe-
nomenon of stationary size of lesions in which progression 
type of “tumor within tumor” occurred (53%), but also often 
pseudocystic lesions were decreasing during progression, 
although usually not significantly (42%).
Conclusions
Since Imatinib was introduced to therapy of inoperative 
and disseminated GIST, CT and MRI have started to pro-
duce unique images, absent or very rarely encountered in 
conventional, cytotoxic chemotherapies used in other types 
of cancers. The possibility of their occurrence in the course 
of GIST treatment may lead to dangerous diagnostic mis-
takes and changes in the right treatment.
Most common are: 
Tumor tissue “fluidization” image. Decrease in density and 
contrast enhancement level may cause transformation of 
primarily solid metastatic tumors in the liver into lesions 
mimicking simple cysts.
Pseudoprogression images. “Appearance of new metasta-
ses” in the liver during actual disease regression, caused by 
visualization of lesions whose contrast enhancement level 
prior treatment did not differ from the surrounding organ 
tissue. Such lesions can be completely invisible in the ini-
tial CT scan, especially when they are small, or get visible 
only in the arterial phase of dynamic study. After decrease 
in attenuation in the course of treatment, the lesions 
become visible and can be misinterpreted as progression, 
with dramatic effects on the patient.
Enlargement of metastatic lesions or their stationary size 
during actual disease regression are quite often encoun-
tered in the early period of chemotherapy. Enlargement 
of lesions, usually nonsignificant, can be caused by their 
abscess, hemorrhage inside tumor or myxoid transforma-
tion. In such cases, decrease in lesion density is the basic 
criterion of positive therapeutic response.
Stationary size of lesions during in course of local disease 
progression – a unique pattern of progression. Metastatic 
lesions, despite no changes in size (standard criterion of 
progression), especially with “cystic” features, can be a 
source of new clones of cancer cells, with genetic muta-
tions determining drug resistance. It is expressed by 
appearance of tiny, better vascularized boundary nodes 
within maternal lesions. These nodes in their early stage 
can be easily overlooked by a radiologist. What is interest-
ing, such new nodal hyperplasias are being observed also 
inside lesions without relation to the “cyst” wall, which 
proves that persistent, alive tumor cells are present also 
within lesions, suspended in the myxoid stroma. Some 
cancer cells surviving the course of therapy is the main 
problem in GIST chemotherapy which makes total cure 
impossible.
Diminishing of some metastatic lesions with concurrent 
enlargement of other lesions or development of new ones. 
Such images are caused by coexistence of metastases show-
ing good response to drug, with new, resistant, expanding 
cell clones. This fact is of uttermost importance for radiolo-
gists evaluating an examination, as every metastatic lesion, 
regardless the other ones, has to be considered as a poten-
tial source of recurrence.
Due to a unique CT image of neoplastic lesions in the course 
of GIST during chemotherapeutic treatment, evaluation of 
treatment response requires application of Choi classifi-
cation instead of RECIST classification. According to Choi 
classification, neoplastic lesions responding well to treat-
ment do not always have to decrease their dimensions, 
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which is a necessary condition according to RECIST classi-
fication. The dimensions of lesions responding positively to 
therapy can remain stationary or even increase. Stationary 
size of lesions after treatment does not necessarily prove 
stability of the neoplastic process. Therefore, the only 
reliable criterion of positive response to treatment accord-
ing to Choi classification is decrease in lesion attenuation, 
which is a proof of decrease in neoplastic tissue vasculariza-
tion. In case of a lesion positively responding to treatment, 
attenuation decrease by 15% or more should be confirmed.
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